Puma Biotechnology (NASDAQ:PBYI) Announces Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Puma Biotechnology (NASDAQ:PBYI) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.12, FiscalAI reports. Puma Biotechnology had a return on equity of 53.15% and a net margin of 20.38%.The business had revenue of $54.48 million during the quarter, compared to analyst estimates of $51.00 million. Puma Biotechnology updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI traded up $1.09 during midday trading on Friday, reaching $5.99. The company’s stock had a trading volume of 2,366,087 shares, compared to its average volume of 490,998. Puma Biotechnology has a one year low of $2.32 and a one year high of $6.07. The company has a market cap of $301.72 million, a price-to-earnings ratio of 6.11 and a beta of 1.35. The company has a 50 day moving average price of $5.02 and a 200 day moving average price of $4.11. The company has a current ratio of 1.73, a quick ratio of 1.62 and a debt-to-equity ratio of 0.10.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on PBYI shares. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings lowered Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Cerity Partners LLC bought a new stake in shares of Puma Biotechnology during the 2nd quarter worth $36,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Puma Biotechnology during the first quarter worth $66,000. Invesco Ltd. lifted its holdings in shares of Puma Biotechnology by 88.9% during the first quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 17,707 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Puma Biotechnology during the second quarter valued at $135,000. Finally, AQR Capital Management LLC boosted its position in shares of Puma Biotechnology by 366.5% in the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 39,641 shares during the period. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.